Trial reportNature medicine2023
Codon-specific KRAS mutations predict survival benefit of trifluridine/tipiracil in metastatic colorectal cancer.
Open access · hybridFull text readRandomized Controlled Trial
In one paragraph
Trial report in Nature medicine, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 58 papers.
0numbers the graph read from it
0cells of the map it votes in
58citing papers in PubMed
18.2field-weighted citation impact, top 1% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
58 citing papers in PubMed, 79 citations in OpenAlex.
- Anlotinib in combination with trifluridine-tipiracil in patients with refractory metastatic colorectal cancers: a phase II, single arm study.The oncologist · 2026Trial
- Overall Survival Analysis of the Phase III CodeBreaK 300 Study of Sotorasib Plus Panitumumab Versus Investigator's Choice in ChemorefractoryJournal of clinical oncology : official journal of the American Society of Clinical Oncology · 2025Trial
- TAS-102, Irinotecan, and bevacizumab in pre-treated metastatic colorectal cancer (TABAsCO), a phase II clinical trial.British journal of cancer · 2024Trial
- Systematic identification of genomic nonresponse biomarkers to cancer therapies.ESMO real world data and digital oncology · 2026Article
- Prior response to anti-VEGF agents predicts the efficacy of trifluridine/tipiracil plus bevacizumab in patients with metastatic colorectal cancer.International journal of clinical oncology · 2026Article
- The clinicopathologic characteristics and outcomes of uncommon KRAS mutations in patients with non-small cell lung cancer.Virchows Archiv : an international journal of pathology · 2026Article
- Single-nucleotide variant profiling in liquid biopsy with RECO-Cas.Science advances · 2026Article
- Review
- A New Era of Salvage-Line Treatment for Metastatic Colorectal Cancer: The Role and Clinical Significance of Circulating Tumor DNA.Biomolecules · 2026Review
- Article
- Screening, Prognostic, and Predictive Molecular Tools for Colorectal Cancer: Recent Advances in the Classical Background.International journal of molecular sciences · 2026Review
- The Molecular and Functional Landscape of Resistance to FOLFIRI Chemotherapy in Metastatic Colorectal Cancer.Cancer discovery · 2026Article
- A real-world study of Trifluridine/Tipiracil (TAS-102) combined with bevacizumab as the late-line treatment of metastatic colorectal cancer.Discover oncology · 2026Article
- Association of RAS mutational status with clinical outcomes in metastatic colorectal cancer treated with trifluridine/tipiracil or regorafenib.Scientific reports · 2026Article
- Article
- KRAS mutations in colorectal cancer patients receiving trifluridine/tipiracil plus bevacizumab: something to consider.ESMO open · 2025Article
- Amplifying mutational profiling of extracellular vesicle mRNA with SCOPE.Nature biotechnology · 2025Article
- Exploring the multifaceted roles of glutamate oxaloacetate transaminase 1 as a biomarker and therapeutic target in colorectal cancer and pan-cancer analyses.Discover oncology · 2025Article
- Analysis of the immune microenvironment in colorectal cancer with different KRAS gene subtypes.BMC cancer · 2025Article
- Design of mismatch closure for enhanced specificity in DNA strand displacement reactions.Nucleic acids research · 2025Article
Corrections and comments
- Commented on by
Authors and funding
50 authors at 20 institutions in 3 countries.
Joris van de HaarDivision of Molecular Oncology & Immunology, The Netherlands Cancer Institute, Amsterdam, the Netherlands.
Xuhui Ma *Division of Molecular Oncology & Immunology, The Netherlands Cancer Institute, Amsterdam, the Netherlands.
Salo N Ooft *Division of Molecular Oncology & Immunology, The Netherlands Cancer Institute, Amsterdam, the Netherlands.ORCID http://orcid.org/0000-0002-3990-3376
Pim W van der Helm *Division of Molecular Oncology & Immunology, The Netherlands Cancer Institute, Amsterdam, the Netherlands.
Louisa R HoesDivision of Molecular Oncology & Immunology, The Netherlands Cancer Institute, Amsterdam, the Netherlands.
Sara MainardiDivision of Molecular Carcinogenesis, The Netherlands Cancer Institute, Amsterdam, the Netherlands.
David J PinatoDepartment of Surgery and Cancer, Imperial College London, Hammersmith Hospital, London, UK.ORCID http://orcid.org/0000-0002-3529-0103
Kristi SunImperial College Healthcare NHS Trust, London, UK.
Lisa SalvatoreOncologia Medica, Comprehensive Cancer Center, Fondazione Policlinico Universitario Agostino Gemelli Istituto di Ricovero e Cura a Carattere Scientifico, Roma, Italy.
Giampaolo TortoraOncologia Medica, Comprehensive Cancer Center, Fondazione Policlinico Universitario Agostino Gemelli Istituto di Ricovero e Cura a Carattere Scientifico, Roma, Italy.ORCID http://orcid.org/0000-0002-1378-4962
Ina Valeria ZurloMedical Oncology, 'Vito Fazzi' Hospital, Lecce, Italy.
Silvana LeoMedical Oncology, 'Vito Fazzi' Hospital, Lecce, Italy.
Riccardo GiampieriDepartment of Oncology, Università Politecnica delle Marche, Azienda Ospedialiera Universitaria delle Marche, Ancona, Italy.
Rossana BerardiDepartment of Oncology, Università Politecnica delle Marche, Azienda Ospedialiera Universitaria delle Marche, Ancona, Italy.
Fabio GelsominoUniversity Hospital of Modena, Modena, Italy.ORCID http://orcid.org/0000-0001-7979-4795
Valeria MerzMedical Oncology Unit, Santa Chiara Hospital, Trento, Italy.
Federica MazzucaDepartment of Clinical and Molecular Medicine, Sapienza University, Oncology Unit, Azienda Ospedialiera Universitaria Sant'Andrea, Rome, Italy.
Lorenzo AntonuzzoClinical Oncology Unit, Careggi University Hospital, Florence, Italy.
Gerardo RosatiMedical Oncology Unit, S. Carlo Hospital, Potenza, Italy.
Chara StavrakaSchool of Cancer & Pharmaceutical Sciences, King's College London, Guy's Hospital, London, UK.
Paul RossDepartment of Medical Oncology, Guy's and St Thomas' NHS Foundation Trust, London, UK.
Maria Grazia RodriquenzIstituto di Ricovero e Cura a Carattere Scientifico Casa Sollievo della Sofferenza, San Giovanni Rotondo, Italy.
Michele PavaranaOncology Unit, Azienda Ospedaliera Universitaria Integrata, Verona, Italy.
Carlo MessinaOncology Unit, ARNAS Civico Di Cristina Benfratelli Hospital, Palermo, Italy.
Timothy IvesonUniversity of Southampton, Southampton, UK.
Federica ZorattoUnità Operativa Complessa Oncologia, Ospedale Santa Maria Goretti Latina, Latina, Italy.
Anne ThomasLeicester Cancer Research Centre, University of Leicester, Leicester Royal Infirmary, Leicester, UK.
Elisabetta FenocchioCandiolo Cancer Institute FPO Istituto di Ricovero e Cura a Carattere Scientifico Candiolo, Candiolo, Italy.ORCID http://orcid.org/0000-0001-6679-0955
Margherita RattiAzienda Socio-Sanitaria Territoriale Cremona, Cremona, Italy.
Ilaria DepetrisDivision of Medical Oncology, ASL TO4, Ospedale Civile di Ivrea, Ivrea, Italy.
Massimiliano CergnulUnità Operativa Oncologia Medica, Ospedale Civile di Legnano, Azienda Socio-Sanitaria Territoriale Ovest Milanese, Legnano, Italy.
Cristina MorelliMedical Oncology Unit, Department of Systems Medicine, Tor Vergata University Hospital, Rome, Italy.
Michela LibertiniMedical Oncology Unit, Brescia, Italy.
Alessandro ParisiDepartment of Oncology, Università Politecnica delle Marche, Azienda Ospedialiera Universitaria delle Marche, Ancona, Italy.
Michele De TursiDipartimento di Tecnologie Innovative in Medicina & Odontoiatria, Università G. D'Annunzio, Chieti-Pescara, Chieti, Italy.
Nicoletta ZanalettiExperimental Clinical Abdominal Oncology Unit, Istituto Nazionale Tumori, Istituto di Ricovero e Cura a Carattere Scientifico, Fondazione G. Pascale, Naples, Italy.
Ornella GarroneOncology Unit, Fondazione Istituto di Ricovero e Cura a Carattere Scientifico Ca' Granda Ospedale Maggiore Policlinico, Milan, Italy.
Janet GrahamBeatson West of Scotland Cancer Centre, Glasgow, UK.
Raffaella LongariniSan Gerardo Hospital, Monza, Italy.
Stefania Maria GobbaDivision of Clinical Oncology, Azienda Socio-Sanitaria Territoriale dei Sette Laghi Varese, Varese, Italy.
Angelica PetrilloMedical Oncology Unit, Ospedale del Mare, Naples, Italy.
Emiliano TamburiniOncology and Palliative Care Department, Tricase Hospital, Lecce, Italy.
Nicla La VerdeLuigi Sacco Hospital-Polo Universitario, Azienda Socio-Sanitaria Territoriale Fatebenefratelli Sacco, Milan, Italy.
Fausto PetrelliOncology Unit, Azienda Socio-Sanitaria Territoriale Bergamo Ovest, Treviglio, Italy.ORCID http://orcid.org/0000-0001-9639-4486
Vincenzo RicciMedical Oncology Unit, Azienda Ospedaliera di Rilievo Nazionale 'San Pio', Benevento, Italy.
Lodewyk F A WesselsDivision of Molecular Carcinogenesis, The Netherlands Cancer Institute, Amsterdam, the Netherlands.ORCID http://orcid.org/0000-0002-1656-6995
Michele GhidiniOncology Unit, Fondazione Istituto di Ricovero e Cura a Carattere Scientifico Ca' Granda Ospedale Maggiore Policlinico, Milan, Italy.
Alessio CortelliniDepartment of Surgery and Cancer, Imperial College London, Hammersmith Hospital, London, UK.ORCID http://orcid.org/0000-0002-1209-5735
Emile E VoestDivision of Molecular Oncology & Immunology, The Netherlands Cancer Institute, Amsterdam, the Netherlands. e.voest@nki.nl.ORCID http://orcid.org/0000-0001-8249-9586
Nicola ValeriDepartment of Surgery and Cancer, Imperial College London, Hammersmith Hospital, London, UK. n.valeri@imperial.ac.uk.ORCID http://orcid.org/0000-0002-5426-5683
The Netherlands Cancer Institute · NLMarche Polytechnic University · ITAzienda Socio Sanitaria Territoriale Lariana · ITFondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico · ITOspedale Vito Fazzi · ITUniversità Cattolica del Sacro Cuore · ITAzienda di Rilievo Nazionale ed Alta Specializzazione · ITAzienda Ospedaliera Ospedale Civile di Legnano · ITAzienda Ospedaliera San Gerardo · ITAzienda Ospedaliera Sant'Andrea · ITAzienda Ospedaliera Universitaria Integrata Verona · ITAzienda Ospedaliero-Universitaria Careggi · ITBeatson West of Scotland Cancer Centre · GBCandiolo Cancer Institute · ITCasa Sollievo della Sofferenza · ITGuy's and St Thomas' NHS Foundation Trust · GBGuy's Hospital · GBHammersmith Hospital · GBImperial College Healthcare NHS Trust · GBInstitute of Cancer Research · GB
Funding
Cancer Research UK (CRUK) A18052Cancer Research UK (CRUK) A26815Wellcome TrustWellcome Trust (Wellcome) PS3416
Abstract
Genomics has greatly improved how patients with cancer are being treated; however, clinical-grade genomic biomarkers for chemotherapies are currently lacking. Using whole-genome analysis of 37 patients with metastatic colorectal cancer (mCRC) treated with the chemotherapy trifluridine/tipiracil (FTD/TPI), we identified KRAS codon G12 (KRAS
Indexed as
Colonic NeoplasmsColorectal NeoplasmsFrontotemporal DementiaRectal NeoplasmsAntineoplastic Combined Chemotherapy ProtocolsDrug CombinationsHumansMutationProto-Oncogene Proteins p21(ras)PyrrolidinesThymineTrifluridineUracilDrug CombinationsKRAS protein, humanProto-Oncogene Proteins p21(ras)PyrrolidinesThyminetipiracilTrifluridineUracil
Identifiers
What OpenQuestion holds
Textfull text, public
LicenceCC BY
measurements read55
identifiers read2
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.